| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/31/2002 | CA2416761A1 Method for screening peptides for use in immunotherapy |
| 01/31/2002 | CA2416751A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | CA2416750A1 Compounds having mif antagonist activity |
| 01/31/2002 | CA2416733A1 Nk cells activating receptors and their therapeutic and diagnostic uses |
| 01/31/2002 | CA2416691A1 Proteases |
| 01/31/2002 | CA2416676A1 Nucleic acids comprising regions of the rat peg-3 promoter and uses thereof |
| 01/31/2002 | CA2416664A1 Zinc finger domain recognition code and uses thereof |
| 01/31/2002 | CA2416643A1 Ghrelin antagonists |
| 01/31/2002 | CA2416608A1 Pharmaceutically active compound |
| 01/31/2002 | CA2416544A1 Mu-conopeptides |
| 01/31/2002 | CA2416538A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/31/2002 | CA2416537A1 Calcilytic compounds |
| 01/31/2002 | CA2416414A1 Human kinases |
| 01/31/2002 | CA2416358A1 Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type i interferons |
| 01/31/2002 | CA2415862A1 Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma |
| 01/31/2002 | CA2415742A1 N-substituted indoles useful in the treatment of diabetes |
| 01/31/2002 | CA2415740A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 01/31/2002 | CA2415585A1 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 01/31/2002 | CA2415077A1 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | CA2415046A1 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide |
| 01/31/2002 | CA2413851A1 Modified virus having an altered tropism |
| 01/31/2002 | CA2412626A1 Il-17 molecules and uses thereof |
| 01/31/2002 | CA2412392A1 Use of estramustine phosphate in the treatment of bone metastasis |
| 01/31/2002 | CA2410683A1 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs |
| 01/31/2002 | CA2410562A1 Colchinol derivatives as angiogenesis inhibitors |
| 01/31/2002 | CA2354236A1 Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| 01/30/2002 | EP1176145A1 Novel guanidino derivatives as inhibitors of cell adhesion |
| 01/30/2002 | EP1176134A1 Ligands of nuclear receptors ppar's |
| 01/30/2002 | EP1175911A2 Uses of recombinant colony stimulating factor-1 for treatment of leukopenia |
| 01/30/2002 | EP1175909A2 Therapeutic methods and compositions based on serrate proteins and nucleic acids |
| 01/30/2002 | EP1175616A1 Methods for the diagnosis and treatment of metastatic prostate tumors |
| 01/30/2002 | EP1175503A1 49 human secreted proteins |
| 01/30/2002 | EP1175498A2 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells |
| 01/30/2002 | EP1175497A2 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| 01/30/2002 | EP1175491A1 Recombinant protein uk114 and its use in therapy and diagnostics |
| 01/30/2002 | EP1175490A2 Tyrosine kinase substrate (tks) proteins |
| 01/30/2002 | EP1175489A1 Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same |
| 01/30/2002 | EP1175446A1 Human antibodies that bind human il-12 and methods for producing |
| 01/30/2002 | EP1175445A1 Specific antibodies and antibody fragments for tgfbeta1 |
| 01/30/2002 | EP1175444A1 Amino-terminal modified parathyroid hormone (pth) analogs |
| 01/30/2002 | EP1175442A2 Osteopontin-derived chemotactic and inhibitory agents and uses therefor |
| 01/30/2002 | EP1175440A1 48 human secreted proteins |
| 01/30/2002 | EP1175436A2 Transiently immortalized cells for use in gene therapy |
| 01/30/2002 | EP1175430A1 Antisense-oligos with better stability and antisense effect |
| 01/30/2002 | EP1175422A2 Tetracyclic progesterone receptor modulator compounds and methods |
| 01/30/2002 | EP1175413A1 2,1-benzisothiazoline 2,2-dioxides |
| 01/30/2002 | EP1175412A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| 01/30/2002 | EP1175411A1 Cyclothiocarbamate derivatives as progesterone receptor modulators |
| 01/30/2002 | EP1175404A1 Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| 01/30/2002 | EP1175398A1 Indoline derivatives as progesterone antagonists |
| 01/30/2002 | EP1175397A1 3,3-substituted indoline derivatives |
| 01/30/2002 | EP1175227A1 Monoclonal antibody directed against cells of human renal cell carcinoma |
| 01/30/2002 | EP1175223A2 Methods and compositions for modulating an immune response |
| 01/30/2002 | EP1175214A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 01/30/2002 | EP1173153A4 Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants |
| 01/30/2002 | EP1045897B1 Enzyme catalyzed therapeutic agents |
| 01/30/2002 | EP1019395B1 Farnesyl transferase inhibiting 2-quinolone derivatives |
| 01/30/2002 | EP0942920B1 Steroid esters, method for the manufacture thereof and their pharmaceutical use |
| 01/30/2002 | EP0934267B1 Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors |
| 01/30/2002 | EP0904539A4 Inhibiting protein interactions |
| 01/30/2002 | EP0904284B1 6-substituted amino-4-oxa-1-azabicyclo[3.2.0]heptan-7-one derivatives as cysteine protease inhibitors |
| 01/30/2002 | EP0891187B1 Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents |
| 01/30/2002 | EP0614355B1 Antitumor vaccines |
| 01/30/2002 | EP0497922B1 Infective protein delivery system |
| 01/30/2002 | CN1333830A Compositions and methods for therapy and diagnosis of ovarian cancer |
| 01/30/2002 | CN1333829A Polypeptide |
| 01/30/2002 | CN1333820A Recombinant methods and materials for producing epothilone and eopthilone derivatives |
| 01/30/2002 | CN1333784A Benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333781A Benzylglycosylamides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333780A Benzylglycosylmmides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333779A Benzyllactobionamides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333778A Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333766A Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds as factor xainhibitors |
| 01/30/2002 | CN1333758A Substituted bicyclic derivatives useful as anticancer agents |
| 01/30/2002 | CN1333755A Benzimidazole compounds that are vitronectin receptor antagonists |
| 01/30/2002 | CN1333754A Benzoheterocycles and their use as MEK inhibitors |
| 01/30/2002 | CN1333698A Combination chemotherapy |
| 01/30/2002 | CN1333694A Stable amorphous amifostine compositions and methods for the preparation and use of same |
| 01/30/2002 | CN1333693A ordered molecualr presentation of antigens, method of preparation and use |
| 01/30/2002 | CN1333689A Method for killing tumor and tumor associated endothelial cells using adenoviral mutants |
| 01/30/2002 | CN1333651A Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method |
| 01/30/2002 | CN1333359A Novel polypeptide--human protein phosphatase 13.31 and polynucleotide for encoding said polypeptide |
| 01/30/2002 | CN1333353A Novel polypeptide--phosphoenolpyruvate dependent saccharophosphotransferase 33 and polynucleotide for encoding said polypeptide |
| 01/30/2002 | CN1333347A Novel polypeptide--human reduced coenzyme I dehydrogenase subunit I-12.43 and polynucleotide for encoding said polypeptide |
| 01/30/2002 | CN1333339A Polytype gene of MXA protein and application thereof |
| 01/30/2002 | CN1333338A Papilloma pseudovirus and process for preparing same |
| 01/30/2002 | CN1333291A Novel polypeptide--human double-stranded RNA conjugated protein 11 and polynucleotide for encoding said polypeptide |
| 01/30/2002 | CN1333286A Novel polypeptide--human growth hormone receptor 14.3 and polynucleotide for encoding said polypeptide |
| 01/30/2002 | CN1333261A Novel polypeptide--human large protein 10.23 and polynucleotide for encoding said polypeptide |
| 01/30/2002 | CN1333256A Novel polypeptide--human transcription regulatory factor ZFM1 isomer 25.63 and polynucleotide for encoding said polypeptide |
| 01/30/2002 | CN1333255A Novel polypeptide--human retina tumor conjugated protein 19.91 and polynucleotide for encoding said polypeptide |
| 01/30/2002 | CN1333242A Novel polypeptide--human tropomyosin 25.08 and polynucleotide for encoding said polypeptide |
| 01/30/2002 | CN1333212A pregnanedione compound, preparation method and use |
| 01/30/2002 | CN1333059A Medicinal composition containing glutathione or its salt |
| 01/30/2002 | CN1333051A Medicine for preventing and treating cancer and preparation process thereof |
| 01/30/2002 | CN1333050A Traditional Chinese medicine for treating cancer |
| 01/30/2002 | CN1333048A Medicine for treating tumor and preparation process thereof |
| 01/30/2002 | CN1333046A Xiangshen injection and preparation process and use thereof |
| 01/30/2002 | CN1333045A Xiangshen soft capsule and preparation process and use thereof |
| 01/30/2002 | CN1333021A Serum preparation with function of resisting tumor and preparation process and use thereof |